Theralase Technologies Stock Price To Sales
| TLT Stock | CAD 0.27 0.01 3.57% |
Theralase Technologies fundamentals help investors to digest information that contributes to Theralase Technologies' financial success or failures. It also enables traders to predict the movement of Theralase Stock. The fundamental analysis module provides a way to measure Theralase Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Theralase Technologies stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 42.54 | 40.42 |
Theralase | Price To Sales |
Theralase Technologies Company Price To Sales Analysis
Theralase Technologies' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Theralase Technologies Price To Sales | 72.67 X |
Most of Theralase Technologies' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theralase Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Theralase Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Theralase Technologies is extremely important. It helps to project a fair market value of Theralase Stock properly, considering its historical fundamentals such as Price To Sales. Since Theralase Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Theralase Technologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Theralase Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Theralase Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Theralase Technologies has a Price To Sales of 72 times. This is 239.57% higher than that of the Health Care Equipment & Supplies sector and notably higher than that of the Health Care industry. The price to sales for all Canada stocks is notably lower than that of the firm.
Theralase Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theralase Technologies' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theralase Technologies could also be used in its relative valuation, which is a method of valuing Theralase Technologies by comparing valuation metrics of similar companies.Theralase Technologies is currently under evaluation in price to sales category among its peers.
Theralase Technologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Theralase Technologies from analyzing Theralase Technologies' financial statements. These drivers represent accounts that assess Theralase Technologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Theralase Technologies' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 38.8M | 77.6M | 66.5M | 39.6M | 35.6M | 23.4M | |
| Enterprise Value | 31.0M | 74.0M | 65.5M | 39.9M | 35.9M | 21.8M |
Theralase Fundamentals
| Return On Equity | -2.39 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (11.30) % | ||||
| Current Valuation | 66.89 M | ||||
| Shares Outstanding | 245.54 M | ||||
| Shares Owned By Insiders | 8.70 % | ||||
| Number Of Shares Shorted | 42.79 K | ||||
| Price To Earning | (9.79) X | ||||
| Price To Book | 31.28 X | ||||
| Price To Sales | 72.67 X | ||||
| Revenue | 1.07 M | ||||
| Gross Profit | 628.17 K | ||||
| EBITDA | (4.31 M) | ||||
| Net Income | (4.57 M) | ||||
| Cash And Equivalents | 1.67 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 386.88 K | ||||
| Current Ratio | 3.45 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (4.07 M) | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 1.2 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 66.3 M | ||||
| Total Asset | 3.28 M | ||||
| Retained Earnings | (63.24 M) | ||||
| Working Capital | 421.43 K | ||||
| Net Asset | 3.28 M |
About Theralase Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theralase Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theralase Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theralase Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Theralase Stock Analysis
When running Theralase Technologies' price analysis, check to measure Theralase Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theralase Technologies is operating at the current time. Most of Theralase Technologies' value examination focuses on studying past and present price action to predict the probability of Theralase Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theralase Technologies' price. Additionally, you may evaluate how the addition of Theralase Technologies to your portfolios can decrease your overall portfolio volatility.